Brief: Suven Life Sciences Says Last Patient Enrolled In Phase 2 Study Of Suvn-502
25/10/2018 08:09
Oct 25 (Reuters) - Suven Life Sciences Ltd SUVP.NS :
* SAYS LAST PATIENT ENROLLED IN PHASE 2 STUDY OF SUVN-502
FOR
MODERATE ALZHEIMER'S DISEASE
Source text for Eikon: ID:nBSE85y5SM
Further company coverage: SUVP.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences Says First Patient Randomized In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences March-Quarter Consol Net Loss 439.4 Million Rupees